How to Prepare:
- Hydrate well, no smoking, no nicotine, no coffee.
- Shower 30 minutes prior to your appointment time.
- Cover your face with a mask or scarf
- Have your identification out and visible at the beginning of the appointment.
- Be prepared to have your temperature taken
How it Works:
- Book Online
- Virtual Consultation
- Service Provider Dispatched
- Specimen is transported to CLIA Certified Lab
- Results in 48-72 hours
COVID-19 lgG & IgM Antibodies
The COVID-19 Antibodies is a serological test that detects human antibodies (proteins belonging to the immunoglobulin class), IgG & IgM. This test is used for screening purposes and designed to complement Real Time RT-PCR in the diagnosis of SARS-CoV-2. This test should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
Nucleic Acid Testing Method TEST [C19]
Swab collection is administered by a healthcare worker using a COVID-19 Collection kit, your sample is sent directly to a State of The Art Laboratory that is CLIA Certified and CAP Accredited where samples are processed and tested that day. The Real Time RT-PCR, DNA instrumentation that they use is cleared by the FDA’s Emergency Use Authorization (EUA).
This test has been validated but independent review by the FDA is not yet complete. This product is intended for professional use and not for home use. Results from antibody testing are presumptive and should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status. A negative result may appear and not correlate with symptoms. A medical professional is required to consider various factors, including confirmation testing, when receiving a presumptive result. This product can only be purchased by a healthcare worker or healthcare company.
Due to the Coronavirus Public Health Emergency, the FDA updated its Policy for Diagnostic Tests for COVID-19 on March 16, 2020. Included in this update is guidance for commercial manufacturers, such as Daizyme., for screening tests and instruments that identify antibodies (e.g., IgM, IgG) to sARS-CoV-2 from clinical specimens. This updated policy allows for testing by healthcare workers at the point of care or in laboratories. At-home testing is not covered by this guidance.
FDA Required Notice:
This test has not been reviewed by the FDA. For use in clinical laboratories by health care professionals following FDA guidance “Policy for Diagnostic Tests for Coronavirus Disease-2019 (COVID-19) during the Public Health Emergency”.
Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic assay should be considered to rule out infection in these individuals.
Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
Not for the screening of donated blood